Managing Retinal Vascular Diseases in Clinical Practice

This episode, titled “Managing Retinal Vascular Diseases in Clinical Practice,” features panelists discussing practical strategies for managing patients with suboptimal responses to anti-VEGF therapy across retinal vascular diseases. The expert faculty explore how they approach treatment adjustment, therapy switching, durability expectations, and patient communication while balancing disease control and long-term visual outcomes.

Throughout the discussion, the panel emphasizes that suboptimal response can present as either persistent retinal fluid or limited durability between injections. The expert faculty review how persistent disease activity may prompt therapy switching, repeat angiographic imaging, or the addition of adjunctive treatments such as photodynamic therapy or corticosteroids in select patients with AMD, DME, or retinal vein occlusion. The panel also discusses the rare but challenging patients who continue to require frequent injections despite second-generation anti-VEGF therapy and how evolving therapeutic mechanisms may help address these unmet needs in the future.

In addition, the expert faculty highlight the importance of patient communication when transitioning therapies or discussing maintenance treatment. The panelists describe how setting realistic expectations regarding disease stability, durability, and long-term management can help patients better understand the goals of therapy. The discussion also explores how second-generation anti-VEGF therapies may support interval extension, even in patients who have remained stable on earlier-generation agents for years. Overall, the panel underscores that individualized treatment planning, patient education, and flexibility in therapeutic decision-making remain essential components of managing retinal vascular diseases in clinical practice.

Our next episode, “Access Challenges in Retinal Vascular Diseases,” features the panelists discussing insurance barriers, treatment adherence, and financial challenges associated with anti-VEGF therapy. The expert faculty also highlight strategies for improving patient access to next-generation therapies while balancing durability, disease control, and long-term treatment burden.